Several therapies explored in SLE ceased further development after unfavorable phase II study results: BT063, a monoclonal antibody targeting IL‐10 (NCT02554019); vobarilizumab, a nanobody against IL‐6 (NCT02437890); PF‐04236921, an IL‐6 monoclonal antibody (NCT01405196)79; and avizakimab, an anti‐IL‐21 monoclonal antibody (NCT03371251). Here, IL6 is linked to systemic lupus erythematosus.